Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Video

David Rubin, MD, on the QUASAR Trial of Guselkumab in Ulcerative Colitis

Dr David Rubin reviews the abstract he presented at the ACG Scientific Meeting on the QUASAR phase 2B study of guselkumab among patients with ulcerative colitis, including those who have not responded to or were intolerant of conventional or biologic therapies.

Advertisement

Advertisement

Advertisement